It’s no surprise that we live in a world of continual technological advancements. The medical field has seen its share of improvements in the way of diagnosing, treating, and understanding many common illnesses such as cancer. As a result, this has led to improvements in the quality of life and recovery rates for many people. Of course, continued research and further advancements are needed. This is why entrepreneurs such as Eric Lefkofsky have made it a mission to continue to positively impact the world of cancer therapies. The information below will discuss more about Eric Lefkofsky and his role in bringing about improved options for the diagnosis and treatment of many common diseases today.
Who is Eric Lefkofsky?
Eric Lefkofsky is an American entrepreneur and founder of Tempus. Mr. Lefskosky has stated that he has always had an entrepreneurial spirit, dipping his toes back in college.
Eric serves as a trustee of the Ann & Robert H. Lurie Children’s Hospital. This facility is well-known for being one of the leading pediatric hospitals in Illinois. In addition, it ranked number 7 in the country overall, proving its value in the ability to affect positive change in the lives of pediatric patients from all walks of life.
Having an active interest in the arts, he is also a trustee for the Art Institute of Chicago. Founded in 1879, the Art Institute of Chicago is well-known for being one of the oldest and largest art museums in America. Mr. Lefkofsky is also involved with the Steppenwolf Theater Company and the Museum of Science and Industry.
What is Tempus?
Tempus is a technology company working to empower physicians to deliver personalized medicine. Its focus is on developing a large database of information that can help physicians make the most informed decisions possible when treating patients.
The overall goal of Tempus as an organization is to bring data to cancer care. At the moment, genomic testing is still in its infancy. Although we are starting to see genetic testing used as part of the diagnostic and treatment process more frequently, the current use is far from where organizations such as Tempus would like to see it. It is believed that at some point in the future, the majority of medical professionals of all types in the US will rely on genomic information in order to provide the best medical care for their patients.
The basis of thought behind genetic testing is quite simple. We all have a unique genetic code that is a large part of what makes us into our own unique individual. Many of these genetic traits overlap in other people from all walks of life. If researchers can effectively pinpoint specific genes that lead to an increased risk of certain diseases such as cancer, this information can be used to help others. Additionally, it is now becoming well-understood that specific genetic factors influence the way an individual will react to certain traditional cancer therapies. By carefully studying and analyzing how genetic factors influence the success of various treatment approaches, medical professionals can already be aware of the types of treatments that are most likely to bring success to other patients. This can eliminate wasted time in trying different approaches that may not bring the best results for that specific individual. The goal for Tempus is for every current and future cancer patient to benefit from the experiences and treatment methodologies of cancer patients who have come before him or her. In essence, Tempus would like to eventually create an enormous database of cancer-related genomic and clinical data that medical professionals can use to help pinpoint specific treatment methods that will yield the best outcome for each patient.
Diseases such as cancer in its various forms affect millions of Americans every year. It is the hope of entrepreneurs like Eric Lefkofky that advancements in technology, especially in areas such as genetic testing and data storage, may hold the key for changing the way medical professionals diagnose and treat cancer today. In this way, it may be possible to change the lives of countless people affected by this disease each year.